Syntex' nafarelin
Executive Summary
NDA for the treatment of endometriosis is expected to be filed by the end of the company's current fiscal year (July 31), Syntex Chairman Albert Bowers told analysts in New York Jan. 18. Bowers also noted that the company has four NDAs pending at the agency, including Cardene, Ticlid, Gardrin and Toradol. The injectable pain killer Toradol (ketorolac) has been given a 1-B rating by the agency, Bowers said.